Abstract
A COMPREHENSIVE REVIEW OF INFLIXIMAB AS A TARGETED THERAPEUTIC CHOICE IN INFLAMMATORY DISORDERS

Rajamanickam Palaniyappan*, Saravanakumar Arthanari, Mohanraj Subramanian, Ragupathi Ganesan, Anandharaj Govindaraj, Mukesh Kumar, Pragadeesh Kandhasamy, Mahadurai Gopal, Janani Thangarasu, Induja Manikantan and Sweatha Dhandapani

ABSTRACT

Infliximab is a potent monoclonal antibody that has revolutionized the treatment of various inflammatory and autoimmune diseases. This captivating abstract takes you on a captivating journey through the world of infliximab, unraveling its mechanism of action, adverse effect, contraindication, outstanding efficacy. The drug infliximab was developed by Jan vilcek at New York university school of medicine and by the centocor company. Firstly, the drug infliximab approved by United States of America for the treatment of fistulizing disease and Crohn's disease. The drug infliximab first known as cA2, which is now marketed as Remicade. At the core of infliximab's triumph lies its remarkable ability to target tumor necrosis factor-alpha (TNF-α). Infliximab efficiently inhibits the inflammatory signaling system by preferentially binding to tumor necrosis factor-alpha (TNF-α), resulting in significant decreases in disease activity. Approximately 100% when administered intravenously due to its direct entry into the systemic circulation. This high bioavailability contributes to its consistent and predictable therapeutic effects. Many clinical studies demonstrated infliximab's excellent effectiveness. Infliximab is not manufactured chemically. It is a monoclonal antibody produced using recombinant DNA technology. While infliximab presents multiple benefits it is critical to be aware of any potential side effects. Among the recognized dangers of infliximab medication include infusion reactions, increased susceptibility to infections, and Malignancy and then it is contraindicated with heart failure, severe hypersensitivity reaction.

Keywords: Remicade, monoclonal antibody, tumor necrosis factor-alpha, immunosuppressive agent.


[Full Text Article]   [Download Certificate]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation

  • EJBPS: APRIL ISSUE PUBLISHED

    APRIL 2024 Issue has been successfully launched on 1 APRIL 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT